ReviewCurrent oncology (Toronto, Ont.)2022
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- METTL3 Increases Temozolomide Resistance in MGMT-Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an mCNS neuroscience & therapeutics · 2026Article
- Same-session hybrid surgery for multifocal glioblastoma: integrating open resection with laser interstitial thermal therapy. Illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Role of Bevacizumab in Multiple Glioblastomas: A Retrospective Single-Center Analysis.Neurosciences (Riyadh, Saudi Arabia) · 2026Article
- Case Report: Rare presentations of glioblastoma: three multifocal and one cerebellar cases highlighting the value of shared clinical experience.Frontiers in oncology · 2026Article
- Sex-Related Differences in Glioblastoma: A Single-Center Retrospective Cohort Study.Biomedicines · 2025Article
- The Prognostic Value of the Systemic Immune-Inflammation Index in Glioblastoma Patients and the Establishment of a Nomogram.Current medical science · 2025Article
- Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response.Radiation oncology journal · 2025Article
- Article
- Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database.Frontiers in pharmacology · 2025Article
- CAR T cell therapy for central nervous system solid tumors: current progress and future directions.Frontiers in immunology · 2025Review
- Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.Journal of neuro-oncology · 2024Article
- In Situ Light-Source Delivery During 5-Aminulevulinic Acid-Guided High-Grade Glioma Resection: Spatial, Functional and Oncological Informed Surgery.Biomedicines · 2024Article
- Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study.Neuro-oncology practice · 2024Article
- Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes.Current oncology (Toronto, Ont.) · 2024Review
- Differentiation of multiple brain metastases and glioblastoma with multiple foci using MRI criteria.BMC medical imaging · 2024Article
- Dose escalation with simultaneous integrated boost for un-methylated multiple glioblastoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67.Medicina (Kaunas, Lithuania) · 2023Article
- The role of cytoreductive surgery in multifocal/multicentric glioblastomas.Journal of neuro-oncology · 2023Article
- Prognostic factors affecting outcome of multifocal or multicentric glioblastoma: A scoping review.Journal of neurosciences in rural practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastomas with multiple foci at presentation (mGBMs) account for 2-35% of all GBMs. mGBMs have limited existing data and no standardized treatment. This study aims to determine their incidence, demographic and clinical features, outcome, and prognostic factors in terms of overall survival. We performed a monocentric retrospective study, reviewing patients treated at the Istituto Oncologico Veneto. Inclusion criteria were: new diagnosis of GBM and presence of multiple lesions on pre-treatment MRI. ECOG PS was used to evaluate clinical condition, RANO criteria for radiological assessment, and CTCAE v5.0 for treatment-related adverse events. The incidence of newly diagnosed mGBM was 7.2% and the study population consisted of 98 patients. Median age was 63 years, M:F ratio of 1.8:1, and a surgical approach was undertaken in 73 patients (mostly partial resection). MGMT was methylated in 47.5%, and 82 patients received active oncological treatment (65.9% radiotherapy plus temozolomide (RT + TMZ)). The disease control rate with RT + TMZ was 63%. Median OS of the entire study population was 10.2 months (95% CI 6.6-13.8), and median PFS was 4.2 months (95% CI 3.2-5.2). The ECOG PS, the extent of resection, and the RT + TMZ were significant prognostic factors in the univariate analysis for OS, but only the RT + TMZ was a significant independent OS predictor in the multivariate analysis (HR = 3.1, 95% IC 1.3-7.7,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.